The origins of urothelial carcinoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 6, 2010, Pages 865-880

  Cheng, Liang ^a   Davidson, Darrell D ^a   MacLennan, Gregory T ^b   Williamson, Sean R ^a   Zhang, Shaobo ^a   Koch, Michael O ^a   Montironi, Rodolfo ^c   Lopez Beltran, Antonio ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Carcinogenesis; Carcinoma in situ; Dysplasia; Early detection; FGFR3; Field cancerization; Field effect; Molecular genetics; Precursor lesion; TP53 mutation; Transitional cell (urothelial) carcinoma; Tumorigenesis; Urinary bladder; Urothelial carcinoma in situ

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53; TUMOR MARKER;

BLADDER BIOPSY; BLADDER CARCINOMA; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA IN SITU; CLINICAL EXAMINATION; CYSTOSCOPY; EARLY DIAGNOSIS; EPITHELIUM HYPERPLASIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; OPTICAL COHERENCE TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RAMAN SPECTROMETRY; REVIEW; TP53 GENE; TRANSITIONAL CELL CARCINOMA; URINE CYTOLOGY; UROTHELIUM;

CARCINOMA IN SITU; CELL LINEAGE; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 77953774777     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.73     Document Type: Review

References (174)

1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6, 963-968 (1953).
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
3. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, France (2004).
4. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press, Lyon, France (2001).
5. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66, 4-34 (2005).
6. Cohen SM, Shirai T, Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand. J. Urol. Nephrol. Suppl. S205, 105-115 (2000). (Pubitemid 32056470)
7. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 374(9685), 239-249 (2009).
8. Hartge P, Harvey EB, Linehan WM et al. Unexplained excess risk of bladder cancer in men. J. Natl Cancer Inst. 82, 1636-1640 (1990).
9. Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J. Urol. 21, 392-401 (2004).
10. Dinney CP, McConkey DJ, Millikan RE et al. Focus on bladder cancer. Cancer Cell 6, 111-116 (2004).
11. Cheng L, Lopez-Beltran A, MacLennan GT, Montironi R, Bostwick DG. Neoplasms of the urinary bladder. In: Urologic Surgical Pathology (2nd Edition). Bostwick DG, Cheng L (Eds). Elsevier/Mosby, PA, USA 259-352 (2008).
12. Lopez-Beltran A, Cheng L. Histologic variants of urothelial carcinoma: differential diagnosis and clinical implications. Hum. Pathol. 37, 1371-1388 (2006).
13. Bostwick DG, Ramnani DM, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol. Clin. N. Am. 26, 493-507 (1999).
14. Bostwick DG. Natural history of early bladder cancer. J. Cell Biochem. 161(Suppl.), 31-38 (1992).
15. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am. J. Surg. Pathol. 23, 443-447 (1999).
16. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Flat intraepithelial lesions of the urinary bladder. Cancer 88, 625-631 (2000).
17. Morton MJ, Zhang S, Lopez-Beltran A et al. Telomere shortening and chromosomal abnormalities in intestinal metaplasia of the urinary bladder. Clin. Cancer Res. 13, 6232-6236 (2007).
18. Sung MT, Lopez-Beltran A, Eble JN et al. Divergent pathway of intestinal metaplasia and cystitis glandularis of the urinary bladder. Mod. Pathol. 19, 1395-1401 (2006).
19. Cheng L, Cheville JC, Neumann RM et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 85, 2469-2474 (1999). (Pubitemid 29244858)
20. Cheng L, Cheville JC, Sebo TJ, Eble JN, Bostwick DG. Atypical nephrogenic metaplasia of the urinary tract: a precursor lesion? Cancer 88, 853-861 (2000).
21. Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum. Pathol. 41, 155-162 (2010).
22. Lopez-Beltran A, Cheng L, Andersson L et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch. 440, 3-11 (2002).
23. Jones TD, Wang M, Eble JN et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin. Cancer Res. 11, 6512-6519 (2005).
24. Koss LG, Tiamson EM, Robbins MA. Mapping cancerous and precancerous bladder changes. A study of the urothelium in ten surgically removed bladders. JAMA 227, 281-286 (1974).
25. Weinstein RS. Origin and dissemination of human urinary bladder carcinoma. Semin. Oncol. 6, 149-156 (1979).
26. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol. 127, 250-252 (1982).
27. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J. Urol. 150, 60-64 (1993).
28. Mazzucchelli R, Barbisan F, Stramazzotti D et al. Chromosomal abnormalities in macroscopically normal urothelium in patients with bladder pT1 and pT2a urothelial carcinoma: a fluorescence in situ hybridization study and correlation with histologic features. Anal. Quant. Cytol. Histol. 27, 143-151 (2005).
29. Cheng L, MacLennan GT, Pan CX et al. Allelic loss of the active X chromosome during bladder carcinogenesis. Arch. Pathol. Lab. Med. 128, 187-190 (2004).
30. Davidson DD, Cheng L. Field cancerization in the urothelium of the bladder. Anal. Quant. Cytol. Histol. 28, 337-338 (2006).
31. Droller MJ. Bladder cancer: State-of-theart care. CA Cancer J. Clin. 48, 269-284 (1998).
32. Cheng L, Gu J, Ulbright TM et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer 94, 104-110 (2002).
33. Jones TD, Carr MD, Eble JN, Wang M, Lopez-Beltran A, Cheng L. Clonal origin of lymph node metastases in bladder carcinoma. Cancer 104, 1901-1910 (2005).
34. Paterson RF, Ulbright TM, MacLennan GT et al. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer 98, 1830-1836 (2003).
35. Sidransky EA, Frost P, von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N. Engl. J. Med. 326, 737-740 (1992).
36. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 342, 1087-1088 (1993).
37. Miyao N, Tsai YC, Lerner SP et al. Role of chromosome 9 in human bladder cancer. Cancer Res. 53, 4066-4070 (1993).
38. Xu X, Stower MJ, Reid IN, Garner RC, Burns PA. Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. Clin. Cancer Res. 2, 1795 - 1800 (1996).
39. Chern HD, Becich MJ, Persad RA et al. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of p53 and retinoblastoma proteins. J. Urol. 156, 1846-1849 (1996).
40. Takahashi T, Kakehi Y, Mitsumori K et al. Distinct microsatellite alterations in upper urinary tract tumors and subsequent bladder tumors. J. Urol. 165, 672-677 (2001).
41. Takahashi T, Habuchi T, Kakehi Y et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res. 58, 5835-5841 (1998).
42. Li M, Cannizzaro LA. Identical clonal origin of synchronous and metachronous low-grade, noninvasive papillary transitional cell carcinomas of the urinary tract. Hum. Pathol. 30, 1197-1200 (1999).
43. Fadl-Elmula I, Gorunova L, Mandahl N et al. Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding. Br. J. Cancer 81, 6-12 (1999).
44. Hartmann A, Rosner U, Schlake G et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab. Invest. 80, 709-718 (2000).
45. Hafner C, Knuechel R, Zanardo L et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene 20, 4910-4915 (2001).
46. Simon R, Eltze E, Schafer KL et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. 61, 355-362 (2001).
47. Goto K, Konomoto T, Hayashi K et al. p53 mutations in multiple urothelial carcinomas: a molecular analysis of the development of multiple carcinomas. Mod. Pathol. 10, 428-437 (1997).
48. Spruck CH 3rd, Ohneseit PF, Gonzalez Zulueta M et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54, 784-788 (1994).
49. Petersen I, Ohgaki H, Ludeke BI, Kleihues P. p53 mutations in phenacetinassociated human urothelial carcinomas. Carcinogenesis 14, 2119-2122 (1993).
50. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am. J. Pathol. 154, 721-727 (1999).
51. Yoshimura I, Kudoh J, Saito S, Tazaki H, Shimizu N. p53 gene mutation in recurrent superficial bladder cancer. J. Urol. 153, 1711-1715 (1995).
52. Stoehr R, Hartmann A, Hiendlmeyer E, Murle K, Wieland W, Knuechel R. Oligoclonality of early lesions of the urothelium as determined by microdissection-supported genetic analysis. Pathobiology 68, 165-172 (2000).
53. Hartmann A, Schlake G, Zaak D et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 62, 809-818 (2002).
54. Cianciulli AM, Leonardo C, Guadagni F et al. Genetic instability in superficial bladder cancer and adjacent mucosa: an interphase cytogenetic study. Hum. Pathol. 34, 214-221 (2003).
55. Junker K, Boerner D, Schulze W, Utting M, Schubert J, Werner W. Analysis of genetic alterations in normal bladder urothelium. Urology 62, 1134-1138 (2003).
56. Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int. J. Cancer 101, 1-6 (2002).
57. Cheng L, Zhang D. Molecular Genetic Pathology. Humana Press/Springer, NY, USA (2008).
58. Cheng L, Zhang S, Davidson DD, Montironi R, Lopez-Beltran A. Implications of cancer stem cells for cancer therapy. In: Stem Cells and Cancer. Bagley RG, Teicher BA (Eds). Humana Press/Springer, NY, USA 255-262 (2009).
59. Cheng L, Zhang S, Davidson DD et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol. 5, 843-857 (2009).
60. Cheng L, Zhang S, Davidson DD, Montironi R, Lopez-Beltran A. Implications of cancer stem cells for cancer therapy. In: Cancer Drug Discovery and Develepment: Stem Cells and Cancer. Bagley RG, Teicher BA (Eds). Humana Press/Springer, NY, USA (2009).
61. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N. Engl. J. Med. 355, 1253-1261 (2006).
62. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer 5(9), 713-725 (2005).
63. Yang YM, Chang JW. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest. 26, 725-733 (2008).
64. Ben-Porath I, Thomson MW, Carey VJ et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008).
65. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24, 778-789 (2006).
66. Sung MT, Wang M, MacLennan GT et al. Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J. Pathol. 211, 420-430 (2007).
67. Cheng L, Jones TD, McCarthy RP et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am. J. Pathol. 166, 1533-1539 (2005).
68. Chan KS, Espinosa I, Chao M et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl Acad. Sci. USA 106(33), 14016-14021 (2009).
69. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 63(8), 1727-1730 (2003).
70. Chow NH, Cairns P, Eisenberger CF et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int. J. Cancer 89, 514-518 (2000).
71. Obermann EC, Junker K, Stoehr R et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J. Pathol. 199, 50-57 (2003).
72. Cheng L, Bostwick DG. Overdiagnosis of bladder carcinoma. Anal. Quant. Cytol. Histol. 30, 261-264 (2008).
73. Sarma KP. Genesis of papillary tumours: histological and microangiographic study. Br. J. Urol. 53, 228-236 (1981).
74. Taylor DC, Bhagavan BS, Larsen MP, Cox JA, Epstein JI. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am. J. Surg. Pathol. 20, 1481-1488 (1996).
75. Swierczynski SL, Epstein JI. Prognostic significance of atypical papillary urothelial hyperplasia. Hum. Pathol. 33, 512-517 (2002).
76. Montironi R, Lopez-Beltran A, Scarpelli M, Mazzucchelli R, Cheng L. Morphological classification and definition of the benign, preneoplastic and non-invasive neoplastic lesions of the urinary bladder. Histopathology 53, 621-633 (2008).
77. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L. Morphological diagnosis of urothelial neoplasms. J. Clin. Pathol. 61, 3-10 (2008).
78. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br. J. Urol. 78, 870-875 (1996).
79. Emerson RE, Cheng L. Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal. Quant. Cytol. Histol. 27, 301-316 (2005).
80. Mallofre C, Castillo M, Morente V, Sole M. Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod. Pathol. 16, 187-191 (2003).
81. McKenney JK, Desai S, Cohen C, Amin MB. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and nonneoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am. J. Surg. Pathol. 25, 1074-1078 (2001).
82. Shirai T, Fukushima S, Hirose M, Ohshima M, Ito N. Epithelail lesions of the urinary bladder in 313 autopsy cases. Jpn. J. Cancer Res. 78, 1073-1080 (1987).
83. Zuk R, Rogers H, Martin J, Baithun S. Clinicopathological importance of primary dsyplasia of bladder. J. Clin. Pathol. 41, 1277-1280 (1988).
84. Baithun S, Rogers H, Martin J, Zuk R, Blandy J. Primary dysplasia of bladder. Lancet 1(8583), 483 (1988).
85. Cooper P, Waisman J, Johnston W, Skinner D. Severe atypia of transitional epithelium and carcinoma of the urinary bladder. Cancer 31, 1055-1060 (1973).
86. Eisenberg R, Roth R, Schweinsberg M. Bladder tumors and associated proliferative mucosal lesions. J. Urol. 84, 544-550 (1960).
87. Harewood LM. The significance of urothelial dysplasia as diagnosed by cup biopsies. Aust. NZ J. Surg. 56, 199-203 (1986).
88. Kakizoe T, Matumoto K, Nishio Y, Ohtani M, Kishi K. Significance of carcinoma in situ and dysplasia association with bladder cancer. J. Urol. 133, 395-398 (1985).
89. Schade RO, Swinney J. Pre-cancerous changes in bladder epithelium. Lancet 2, 943-946 (1968).
90. Wolf H, Hojgaard K. Urothelial dysplasia in random mucosal biopsies from patients with bladder tumors. Scand. J. Urol. Nephrol. 14, 37-41 (1980).
91. Smith G, Elton RA, Beynon LL, Newsam JE, Chisholm GD, Hargreave TB. Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br. J. Urol. 55, 665-669 (1983).
92. Althausen A, Prout G, Daly J. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J. Urol. 116, 575-580 (1976).
93. Gibbons R, Mandler J, Harmann W. The significance of epithelial atypia seen in non-invasive transitional cell papillary tumors of the bladder. J. Urol. 102, 195-199 (1969).
94. Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur. J. Cancer 30A, 1621-1625 (1994).
95. Murphy WM, Nagy GK, Rao MK et al. "Normal" urothelium in patients with bladder cancer: a preliminary report from the National Bladder Cancer Collaborative Group A. Cancer 44, 1050-1058 (1979).
96. Murphy WM, Soloway MS. Developing carcinoma (dysplasia) of the urinary bladder. Pathol. Annu. 17(Pt 1), 197-217 (1982).
97. Murphy WM, Soloway MS. Urothelial dysplasia. J. Urol. 127, 849-854 (1982).
98. Wolf H, Hojgaard K. Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurances. Lancet 2(8342), 134-136 (1983).
99. Wolf H, Olsen P, Hojgaard K. Urothelial dysplasia concomitant with bladder tumours: a determinant for future new occurances in patients treated by fullcourse radiotherapy. Lancet 1(8436), 1005-11000 (1985).
100. Melamed M, Voutsa N, Grabstald H. Natural history and clinical behavior of in situ carcinoma of the human urinary bladder. Cancer 17, 1533-1545 (1964).
101. Hudson MA, Herr HW. Carcinoma in situ of the bladder. J. Urol. 153, 564-572 (1995).
102. Farrow GM, Utz DC. Observation on microinvasive transitional cell carcinoma of the urinary bladder. Clin. Oncol. 1, 609-615 (1982).
103. Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology 35, 484-491 (2003).
104. Farrow G. Pathology of carcinoma in situ of the urinary bladder and related lesions. J. Cell Biochem. 161, 39-43 (1992).
105. Orozco R, Martin A, Murphy W. Carcinoma in situ of the urinary bladder: Clues to host involvement in human carcinogenesis. Cancer 74, 115-122 (1994).
106. Batista J, Palou J, Iglesias J et al. Significance of urethral carcinoma in situ in speciments of cystectomy. Eur. Urol. 25, 313-315 (1994).
107. Khan AU, Farrow GM, Zincke H, Utz DC, Greene LF. Primary carcinoma in situ of the ureter and renal pelvis. J. Urol. 121, 681-683 (1979).
108. Mahadevia PS, Koss LG, Tar IJ. Prostatic involvement in bladder cancer. Prostate mapping in 20 cystoprostatectomy specimens. Cancer 58, 2096-2102 (1986).
109. Farrow G, Utz D, Rife C. Morphological and clinical observations of patients with early bladder cancer treated with total cystectomy. Cancer Res. 36, 2495-2501 (1976).
110. Farrow G, Utz D, Rife C, Greene L. Clinical observations on sixty-nine cases of in situ carcinoma of the urinary bladder. Cancer Res. 37, 2794-2798 (1977).
111. Utz DC, Farrow GM, Rife CC, Segura JW, Zincke H. Carcinoma in situ of the bladder. Cancer 45, 1842-1848 (1980).
112. Lamm DL. Carcinoma in situ. Urol. Clin. North Am. 19, 499-508 (1992).
113. van der Meijden AP, Sylvester R, Oosterlinck W et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur. Urol. 48(3), 363-371 (2005).
114. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180-183 (1976).
115. Lamm DL, Blumenstein BA, Crawford ED et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325, 1205-1209 (1991).
116. Lamm DL. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur. Urol. 27(Suppl. 1), 2-8 (1995).
117. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol. 158, 62-67 (1997).
118. Takenaka A, Yamada Y, Miyake H, Hara I, Fujisawa M. Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder. Int. J. Urol. 15, 309-313 (2008).
119. Talic RF, Hargreave TB, Bishop MC, Kirk D, Prescott S. Intravesical Evans bacille Calmette-Guerin for carcinoma in situ of the urinary bladder. Scottish Urological Oncology Group. Br. J. Urol. 73, 645-648 (1994).
120. Lamm DL, Blumenstein BA, Crissman JD et al. Maintenance bacillus Calmette- Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124-1129 (2000).
121. Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J. Urol. 165, 1488-1491 (2001).
122. Lopez-Beltran A, Luque RJ, Mazzucchelli R, Scarpelli M, Montironi R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J. Clin. Pathol. 55, 641-647 (2002).
123. Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J. Urol. 27, 319-324 (2009).
124. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus Calmette-Guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev. Urol. 10, 281-289 (2008).
125. Swinn MJ, Walker MM, Harbin LJ et al. Biopsy of the red patch at cystoscopy: is it worthwhile? Eur. Urol. 45, 471-474 (2004).
126. Fernando H, Thota SS, Burtt G, Waterfall N, Husain I. Importance of red patches diagnosed in cystoscopy for haematuria and lower urinary tract symptoms. Postgrad. Med. J. 83, 62-63 (2007).
127. Heyerdahl H, Wang I, Liu DL et al. Pharmacokinetic studies on 5-aminolevulinic acid-induced protoporphyrin IX accumulation in tumours and normal tissues. Cancer Lett. 112(2), 225-231 (1997).
128. Witjes JA, Redorta JP, Jacqmin D et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur. Urol. 57(4), 607-614 (2010).
129. Cauberg EC, de Bruin DM, Faber DJ, van Leeuwen TG, de la Rosette JJ, de Reijke TM. A new generation of optical diagnostics for bladder cancer: technology, diagnostic accuracy, and future applications. Eur. Urol. 56, 287-296 (2009).
130. Lange N, Jichlinski P, Zellweger M et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br. J. Cancer 80(1-2), 185-193 (1999).
131. Bourre L, Giuntini F, Eggleston IM, Wilson M, MacRobert AJ. Protoporphyrin IX enhancement by 5-aminolaevulinic acid peptide derivatives and the effect of RNA silencing on intracellular metabolism. Br. J. Cancer 100(5), 723-731 (2009).
132. Kemmner W, Wan K, Ruttinger S et al. Silencing of human ferrochelatase causes abundant protoporphyrin-IX accumulation in colon cancer. FASEB J. 22(2), 500-509 (2008).
133. Peng Q, Warloe T, Berg K et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79(12), 2282-2308 (1997). (Pubitemid 27251011)
134. Fradet Y, Grossman HB, Gomella L et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a Phase III, multicenter study. J. Urol. 178, 68-73 (2007). (Pubitemid 46908730)
135. Burger M, Zaak D, Stief CG et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur. Urol. 52(1), 142-147 (2007).
136. Colombo R, Naspro R, Bellinzoni P et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Ther. Clin. Risk Manag. 3, 1003-1007 (2007).
137. Daniltchenko DI, Riedl CR, Sachs MD et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J. Urol. 174(6), 2129-2133.
138. Ren H, Waltzer WC, Bhalla R et al. Diagnosis of bladder cancer with microelectromechanical systems-based cystoscopic optical coherence tomography. Urology 74(6), 1351-1357 (2009).
139. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 51, 1275-1280 (2007).
140. Lokeshwar VB, Habuchi T, Grossman HB et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66, 35-63 (2005). (Pubitemid 43049608)
141. Horstmann M, Patschan O, Hennenlotter J, Senger E, Feil G, Stenzl A. Combinations of urine-based tumour markers in bladder cancer surveillance. Scand. J. Urol. Nephrol. 43(6), 461-466 (2009).
142. Tetu B. Diagnosis of urothelial carcinoma from urine. Mod. Pathol. 22(Suppl. 2), S53-S59 (2009).
143. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 293, 810-816 (2005).
144. Shariat SF, Marberger MJ, Lotan Y et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J. Urol. 176, 919-926 (2006).
145. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol. 47, 736-748 (2005).
146. Mian C, Maier K, Comploj E et al. uCyt+/ ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 108, 60-65 (2006).
147. Ramakumar S, Bhuiyan J, Besse JA et al. Comparison of screening methods in the detection of bladder cancer. J. Urol. 161, 388-394 (1999).
148. Schroeder GL, Lorenzo-Gomez MF, Hautmann SH et al. A side by side comparison of cytology and biomarkers for bladder cancer detection. J. Urol. 172, 1123-1126 (2004).
149. Soyuer I, Sofikerim M, Tokat F, Soyuer S, Ozturk F. Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression? Diagn. Pathol. 4, 20 (2009).
150. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J. Cancer Res. Clin. Oncol. 134(6), 659-665 (2008).
151. Eissa S, Swellam M, Ali-Labib R, Mansour A, El-Malt O, Tash FM. Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer. J. Urol. 178(3 Pt 1), 1068-1072 (2007).
152. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur. Urol. 52(5), 1388-1396 (2007).
153. Babjuk M, Soukup V, Pesl M et al. Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma. Urology 71, 718-722 (2008).
154. May M, Hakenberg OW, Gunia S et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 70, 449-453 (2007).
155. Gkialas I, Papadopoulos G, Iordanidou L et al. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-21, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma. Urology 72(5), 1159-1163 (2008).
156. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D. Evaluation of urine CYFRA 21-21 for the detection of primary and recurrent bladder carcinoma. Cancer 94, 2914-2922 (2002).
157. Fernandez-Gomez J, Rodriguez- Martinez JJ, Barmadah SE et al. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. Eur. Urol. 51, 1267-1274 (2007).
158. Schneider A, Borgnat S, Lang H et al. Evaluation of microsatellite analysis in urine sediment for diagnosis of bladder cancer. Cancer Res. 60(16), 4617-4622 (2000).
159. van Rhijn BW, Smit M, van Geenen D et al. Surveillance with microsatellite analysis of urine in bladder cancer patients treated by radiotherapy. Eur. Urol. 43(4), 369-373 (2003).
160. Hautmann S, Toma M, Lorenzo Gomez MF et al. Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur. Urol. 46, 466-471 (2004).
161. Lokeshwar VB, Schroeder GL, Selzer MG et al. Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acidhyaluronidase and BTA-Stat tests. Cancer 95, 61-72 (2002).
162. Eissa S, Labib RA, Mourad MS, Kamel K, El-Ahmady O. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. Eur. Urol. 44(6), 687-694 (2003).
163. Halling KC, King W, Sokolova IA et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol. 164, 1768-1775 (2000).
164. Gudjonsson S, Isfoss BL, Hansson K et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur. Urol. 54, 402-408 (2008).
165. Garbar C, Mascaux C, Wespes E. Is urinary tract cytology still useful for diagnosis of bladder carcinomas? A large series of 592 bladder washings using a five-category classification of different cytological diagnoses. CytoPathology 18, 79-83 (2007).
166. Bubendorf L, Grilli B, Sauter G, Mihatsch MJ, Gasser TC, Dalquen P. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am. J. Clin. Pathol. 116, 79-86 (2001).
167. Sarosdy MF, Schellhammer P, Bokinsky G et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol. 168, 1950-1954 (2002).
168. Schwarz S, Rechenmacher M, Filbeck T et al. Value of multicolour fluorescence in situ hybridisation (UroVysion) in the differential diagnosis of flat urothelial lesions. J. Clin. Pathol. 61, 272-277 (2008).
169. Messing EM, Teot L, Korman H et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J. Urol. 174, 1238-1241 (2005).
170. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfill clinical necessity? J. Urol. 165, 1067-1077 (2001).
171. Halling KC, King W, Sokolova IA et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J. Urol. 167, 2001-2006 (2002).
172. Melicow MM, Hollowell JW. Intraurothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J. Urol. 68(4), 763-772 (1952).
173. Melicow MM. Histological study of vesical urothelium intervening between gross neoplasms in total cystectomy. J. Urol. 68(1), 261-279 (1952).
174. Soyuer I, Tokat F, Tasdemir A. Significantly increased accuracy of urothelial carcinoma detection in destained urine slides with combined analysis of standard cytology and CK-20 immunostaining. Acta Cytol. 53(3), 357-360 (2009).